MYL5 as a Novel Prognostic Marker is Associated with Immune Infiltrating in Breast Cancer: A Preliminary Study
Table 2
Kaplan–Meier plotter to determine the effect of different clinicopathological factors on the expression of MYL5 gene and clinical prognosis in breast cancer.
Clinicopathological characteristics
Overall survival (n = 1879)
Relapse free survival (n = 4929)
N
Hazard ratio
-value
N
Hazard ratio
-value
ER status
Positive
1309
0.83 (0.65–1.06)
0.13
3768
0.69 (0.61–0.78)
Negative
570
0.62 (0.43–0.88)
1161
0.73 (0.6–0.89)
PR status
Positive
156
1.5 (0.72–3.16)
0.28
926
0.76 (0.56–1.02)
0.07
Negative
291
0.65 (0.4–1.07)
0.088
925
0.72 (0.54–0.95)
HER2 status
Positive
420
0.78 (0.54–1.13)
0.19
882
0.71 (0.56–0.89)
Negative
1459
0.65 (0.52–0.81)
4047
0.58 (0.51–0.65)
Intrinsic subtype
Basal
404
0.65 (0.44–0.97)
846
0.77 (0.62–0.97)
Luminal A
794
1.29 (0.93–1.78)
0.12
2277
0.66 (0.56–0.78)
Luminal B
515
0.73 (0.5–1.07)
0.11
1491
1.14 (0.94–1.38)
0.19
HER2+
166
0.43 (0.22–0.84)
315
0.67 (0.45–1)
Lymph node status
Positive
452
0.75 (0.54–1.04)
0.086
1656
0.61 (0.52–0.73)
Negative
726
0.53 (0.37–0.76)
2368
0.72 (0.61–0.84)
Grade
1
175
0.49 (0.21–1.18)
0.1
397
0.54 (0.32–0.9)
2
443
0.84 (0.56–1.27)
0.41
1177
0.77 (0.62–0.96)
3
586
0.74 (0.55–1)
0.05
1300
0.75 (0.62–0.9)
TP53 status
Mutated
130
1.83 (0.93–3.63)
0.077
188
1.31 (0.78–2.21)
0.3
Wild type
197
0.33 (0.18–0.62)
273
0.51 (0.32–0.81)
OS: overall survival, RFS: relapse free survival, BRCA, and breast invasive carcinoma. ,,, and .
